Paxman Q1: Initial take – A bit lower sales and higher costs than expected, but no major cause for concern - Redeye

Redeye provides an initial take following Paxman’s Q1 2025 report. The quarterly figures came in slightly below our expectations; however, we see no major cause for concern and remain positive on the company’s outlook. That said, we expect to make some minor downward adjustments to our estimates based on the report, while also incorporating the CIPN segment in our upcoming research update.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109397/paxman-q1-initial-take-a-bit-lower-sales-and-higher-costs-than-expected-but-no-major-cause-for-concern?utm_source=finwire&utm_medium=RSS